June is Men’s Health Month in the USA and the third Sunday of June is celebrated as Father's Day. So in addition to Prostate Cancer Awareness Month in September and "Movember" (grow or wear a mustache in November to show you're "committed to changing the face of men’s health") June is a good time for health organizations to stand up for men. The College of American Pathologists (CAP) does so in an advisory, "5 Things to Know About Your PSA Test."

Misialek-Michael-J-Dr-250px
Michael J. Misialek, MD, Pathologist.

The pathologists' organization suggests that if you're a man "heeding the advice of your wife, girlfriend or significant other," you may have decided this June "to schedule yourself for that routine physical that you've been putting off. One aspect of your visit to the doctor’s office might be a PSA test."

"Your Prostate Specific Antigen screening test," CAP says, "will be studied and evaluated by a pathologist like Michael J. Misialek, MD, FCAP. Dr. Misialek says there’s a lot you need to understand about this test." ...continue reading "Blood Simple – Pathologist Michael Misialek encourages men’s health checkups as the PSA era heads toward Gene Tests and the Prostate Health Index"

SEATTLE, April 29, 2010 --Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) has approved PROVENGE(®) (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC). Provenge is designed to induce an immune response against Prostatic Acid Phosphatase (PAP), an antigen expressed in most prostate cancers, and is the first in a new therapeutic class known as autologous cellular immunotherapies.
...continue reading "FDA Approves PROVENGE ® for the Treatment of Men with Advanced Prostate Cancer"

James Watson, the scientist who was one of the discoverers of the double-helical structure of DNA, says in an op-ed today that the National Cancer Institute (NCI) is "a largely rudderless ship in dire need of a bold captain." Aside from that, Watson is optimistic: ...continue reading "National Cancer Institute a “rudderless ship”"

Kurt Donsbach, 73, who markets supplements including some for conditions of the prostate, was arrested April 8 during his internet radio show "Let's Talk Health" on a warrant charging him with 11 felonies including treating patients without a license, misbranding drugs for sale, grand theft, unlawfully dispensing drugs as a cure for cancer and falsely representing a cure for cancer. Bail was set at $1,500,000.

A San Diego news site reports: "District Attorney Bonnie Dumanis said that Kurt Walter Donsbach, 73, "preyed on vulnerable patients who were looking for medical help."

Arraigned April 13, Donsbach plead not guilty in San Diego's downtown Superior Court. Bail was lowered to $250,00.
...continue reading "Kurt Donsbach Arrested on Health Fraud Charges"

On December 24, 2008 the US Food & Drug Administration granted tentative approval to Accord Healthcare's bicalutamide.

Accord is a subsidiary of Intas Pharmaceuticals, Ltd., an Indian company. Accord's function is licensing and marketing.
...continue reading "Generic Casodex: Tentative US Approval"

In submitting Provenge vaccine for the treatment of advanced prostate cancer for fast-tracked FDA approval despite aborting one clinical trial due to failure to meet the primary endpoint, Dendreon relied on meta-analysis of combined data from two parts of a phase III study, D9901. In fact, after the trials failed to meet their primary endpoint, time to progression, they were analysed twice over. Dr. Eric Small presented meta-analyses of impact on overall survival and prostate cancer specific survival and Dr. Daniel Petrylak presented a further analysis or suvival focused on a subset of patients who, when they progressed on Provenge, took Taxotere.
...continue reading "Provenge and Meta-Analysis — Compare Avandia"